The ceramide synthase family, often referred to as LASS (longevity assurance homologs), encompasses a group of enzymes crucial in sphingolipid metabolism. These enzymes are responsible for the synthesis of ceramides, a type of lipid molecule that plays a key role in cell membrane integrity and signaling pathways. Each ceramide synthase isoform (CerS1-6 in humans) prefers different fatty acyl-CoA substrates, leading to the production of ceramides with distinct acyl chain lengths. The ceramides synthesized by these enzymes are involved in various cellular processes, including apoptosis, cell proliferation, and stress response. Dysregulation of ceramide synthase activity is linked to numerous diseases, including cancer, neurodegenerative disorders, and metabolic conditions. Additionally, ceramides act as signaling molecules, influencing pathways like inflammation and cell survival, and are integral to the formation of lipid rafts in cell membranes.
Targeting ceramide synthase (LASS) for disruption or inhibition using small molecules is a strategic approach for understanding its biological functions and implications in diseases. By selectively inhibiting specific isoforms of ceramide synthase, researchers can elucidate the distinct roles of different ceramide species in cellular processes. Small molecule inhibitors allow for precise modulation of ceramide levels, facilitating studies on how changes in ceramide synthesis affect cellular signaling pathways. This approach is critical for dissecting the complex sphingolipid metabolism pathways and their impact on cell physiology. Inhibiting ceramide synthase can reveal insights into the mechanisms of diseases like cancer, where ceramide levels are often dysregulated.
VER TAMBIÉN ....
| Nombre del producto | NÚMERO DE CAS # | Número de catálogo | Cantidad | Precio | MENCIONES | Clasificación |
|---|---|---|---|---|---|---|
Fumonisin B1 | 116355-83-0 | sc-201395 sc-201395A | 1 mg 5 mg | ¥1320.00 ¥5291.00 | 18 | |
Inhibidor de la ceramida sintasa que puede reducir la actividad de LASS4 inhibiendo competitivamente la función de la enzima. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | ¥2245.00 ¥6758.00 | 24 | |
Este inhibidor no competitivo de la esfingomielinasa neutra podría influir en los niveles de ceramida regulando la expresión de LASS4. | ||||||
Tipifarnib | 192185-72-1 | sc-364637 | 10 mg | ¥8123.00 | ||
Un inhibidor de la farnesiltransferasa, que posiblemente afecta a la modificación postraduccional de las proteínas que regulan LASS4. | ||||||
Ceranib-2 | 1402830-75-4 | sc-507503 | 10 mg | ¥1952.00 | ||
Inhibidor específico de la ceramida sintasa que puede disminuir la actividad de LASS4 por inhibición directa. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | ¥1862.00 | ||
Inhibidor de la autofagia que puede afectar al recambio de componentes celulares, incluido el LASS4. | ||||||
Desipramine hydrochloride | 58-28-6 | sc-200158 sc-200158A | 100 mg 1 g | ¥733.00 ¥1297.00 | 6 | |
Inhibe la esfingomielinasa ácida y podría alterar el metabolismo de los esfingolípidos, lo que podría afectar al LASS4. | ||||||
Bryostatin 1 | 83314-01-6 | sc-201407 | 10 µg | ¥2708.00 | 9 | |
Inhibe la fosfolipasa C específica de la fosfatidilcolina, lo que afecta a la degradación de la esfingomielina y, por extensión, a los niveles de ceramida que pueden influir en el LASS3. | ||||||
SKI II | 312636-16-1 | sc-204286 sc-204286A | 10 mg 50 mg | ¥1061.00 ¥4423.00 | 3 | |
Inhibe la esfingosina cinasa, que puede influir en los niveles de esfingosina-1-fosfato y en la síntesis de ceramida, afectando potencialmente al LASS3. | ||||||
4-Hydroxyphenylretinamide | 65646-68-6 | sc-200900 sc-200900A | 5 mg 25 mg | ¥1173.00 ¥3554.00 | ||
Induce la síntesis de ceramida, influyendo potencialmente en la actividad de LASS3 a través de mecanismos de retroalimentación. | ||||||
Sphingomyelin | 85187-10-6 | sc-201381 sc-201381A | 100 mg 500 mg | ¥1839.00 ¥5867.00 | 3 | |
Bloquea la ceramida sintasa, incluido el LASS3, lo que provoca una disminución de la síntesis de ceramida. | ||||||